Novo Nordisk’s Ibrahim Kamstrup-Akkaoui outlines how the Danish GLP-1 giant is embedding AI into its clinical foundation.

TEL AVIV, Israel, May 17, 2022 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic, fibrosis and ...

New high-value indication for Phase 3-ready asset with data intended to support clinical development and strategic partnering ...

OXFORD, England--(BUSINESS WIRE)--Exscientia plc (Nasdaq: EXAI) today announced the appointment of two technology and clinical development leaders to senior roles to significantly strengthen the ...

Developed in collaboration with Korea's top clinical and hospital network, the integrated platform combines globally ...

VS-7375 (investigational KRAS G12D ON/OFF inhibitor) demonstrates clinical activity with a favorable safety profile in TARGET ...

Parexel, a leading global clinical development partner providing insights-driven Clinical and Consulting solutions to the world’s life sciences industry, today announced the launch of the Parexel ...

From original GLP-1 science to international clinical development, Innogen shares its 'from 0 to 1' innovation journey in metabolic diseases ...

When healthtech and medtech companies fail, it's often not because their innovation lacks merit. It's due to foundational ...

AMPLIFY-7P did not meet the pre-specified primary endpoint of disease-free survival (“DFS”) in the intent-to-treat population.Randomization ...

Wearable sensors remain largely underused, despite their utility in improving data collection and regulatory compliance.